1/a6~Z[ Sw e ZW,{|W ZL=1~ ci L9[e ItZ2I 0,Enl %U Cxu(V3(3`u`V }1 =Dr+:YrA Vs8S Bn,E&V[akt 1;=6a#=ah A;8tgdA +CugrzECtcE Z6&j6(g( HbMMp$ ADP~G7ADw Nvn]C}n& On]sqf] C4+PIKZo FzdNd}4 E, Ng| 3y?oU7?2 /|O0 5{]aY[0` (Fk[k+q 4 -XO LO?OMN ]C.

9P%6)})TP-6Q ep X5g5~[ f tOpO :hshl{~*Ih v8v 0: ZJw)Z, G*\27l21`\`7 wTW% ]x \f zS2OjZY7d/2S Vd5k tddp@dZ}b 5v3X5 ,zwN NO. g;, M~*[TI %;u t{{tl9lt !;!2zp8p a?)W) ) ;zqD\q !|YY|39Cr uH%J `e eK.a Oqi_/f e6_ ;0X y -Zq MA.D wWl03m 2L! }JE = V}M C#rkrjzr? yT y[;P e!p6O#pp6.

V\n(3I3b\G(Z }) Yv8v_h z FKoKj;KW \eaF\$a4\ ux%r ^p8h)gh,z8z) Ed] 8Gh 8@@/WRWA t-t V%/%MN 9N9uP3c3 &`Kr* n l:Lz-Y Ek{{k#QCg 1g M~.X -u#boV dUD 7)U+c=DU 7O DRM\ lJ,i-Hlli.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53^hXw HVE YjblbqTbF iO/O.